● pepmg Research Desk · Peer-reviewed evidence review
What the research says about BPC-157 and tissue repair
A neutral summary of the peer-reviewed literature on BPC-157, a peptide studied almost entirely in animal and in-vitro models for tissue repair. No controlled human trials exist. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- BPC-157 (body protection compound-157) is a peptide studied mainly in animal and in-vitro models for tissue repair; the published work is overwhelmingly preclinical [1][3].
- There are no controlled human trials of BPC-157 for musculoskeletal injury. A 2025 systematic review of 36 studies found 35 were preclinical and just one was a small retrospective human report [3].
- One review notes BPC-157 lacks US FDA approval and is banned in professional sports; this page reports what the studies measured and links to each — it is not dosing, medical, or safety advice [3].
What BPC-157 is
BPC-157 is described in the literature as a stable gastric pentadecapeptide — a short peptide associated with a protein found in gastric juice — investigated for a possible role in tissue protection and healing [2]. Reviews place it in the broad research area of wound- and soft-tissue-repair peptides [1][2].
It is important to separate what has been tested in animals from what has been tested in people. Across these reviews the great majority of the underlying experiments are in rats and other animal models, or in cell systems — not in humans [1][2][3].
What the preclinical research has measured
Preclinical onlyA 2019 review examined BPC-157 as a candidate for accelerating musculoskeletal soft-tissue healing, noting that the relevant therapies were being studied in animal models [1]. A 2021 review summarized reported wound-healing effects — incisional and excisional wounds, burns, and other tissue injuries — largely characterized in rats [2].
A 2025 systematic review in orthopaedic sports medicine screened 544 articles and included 36 studies, of which the authors classified 35 as preclinical and one as clinical [3]. In animal models, the review reported improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injuries, alongside reported effects on growth-factor signaling and inflammation [3].
The single human report in that review was a small retrospective series: of 12 people who received an intra-articular BPC-157 injection for chronic knee pain, 7 reported relief lasting more than six months [3]. The authors describe this as level IV–V evidence and note that no clinical safety data were found [3]. This is a preliminary observation, not a controlled trial.
How strong is the evidence
Because the cited literature is essentially all preclinical — with no controlled human trials — this review is characterized as preclinical only [1][2][3]. Findings in animals do not establish that a compound works, is safe, or behaves the same way in people.
One review states plainly that BPC-157 lacks US Food and Drug Administration approval and that its use is banned in professional sports [3]. Nothing here is an endorsement, an efficacy or safety claim, or dosing guidance. BPC-157 is sold by third parties for laboratory and research use only. Read the underlying studies and consult a qualified professional — this page is a map to the evidence, not a recommendation.
Sources · 3
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.